FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095388504> ?p ?o ?g. }

• W2095388504 endingPage "1462" @default.
• W2095388504 startingPage "1456" @default.
• W2095388504 abstract "We reviewed the literature to help clarify the benefits and/or hazards associated with monitoring serum prostate specific antigen (PSA) after treatment with surgery or radiation therapy (RT) for nonmetastatic prostate cancer.A search was performed for 1990 to 2004 using the MEDLINE database, CancerLit database and reference lists of relevant studies to obtain articles addressing the use of serum PSA to follow patients after treatment for prostate cancer. Studies were reviewed to determine 1) if serial PSA monitoring provides an early and accurate surrogate assessment of cancer cure or treatment failure, 2) if any pattern in the PSA profile after treatment provides conclusive evidence of early local vs systemic failure, 3) the magnitude of the lead time to clinical failure that serial PSA monitoring may provide and 4) if the early identification of biochemical failure (BF) with earlier intervention improves outcome.Although a lower PSA nadir after treatment with RT has been associated with cancer cure, 5% to 25% of patients ultimately have failure (beyond 5 years) even with the most optimal biochemical response. The most appropriate BF definitions to use after treatment for prostate cancer with RT remains controversial due to substantial differences in their accuracy, sensitivity, specificity and positive predictive value for clinical outcome. No pattern of PSA kinetics after treatment has conclusively been associated with a specific recurrence site. Biochemical failure definitions in patients treated with RT appear to provide a 6 to 18 month lead time to clinical failure but there are only limited published data to suggest that early intervention of any type (androgen deprivation, RT, surgery, etc) impacts survival.The overall benefit of monitoring serum PSA after treatment for prostate cancer remains controversial. Considering the potential dangers associated with incorrectly assuming the efficacy of new forms of treatment, the toxicity of administering salvage therapies of uncertain efficacy after BF has been identified and the anxiety associated with tracking posttreatment serum PSA, additional studies must be done to determine the appropriate use of this marker in properly treating patients after therapy." @default.
• W2095388504 created "2016-06-24" @default.
• W2095388504 creator A5006151030 @default.
• W2095388504 creator A5016407136 @default.
• W2095388504 creator A5021503571 @default.
• W2095388504 creator A5034586842 @default.
• W2095388504 creator A5049646055 @default.
• W2095388504 creator A5059255743 @default.
• W2095388504 date "2005-05-01" @default.
• W2095388504 modified "2023-10-04" @default.
• W2095388504 title "LIMITATIONS IN THE USE OF SERUM PROSTATE SPECIFIC ANTIGEN LEVELS TO MONITOR PATIENTS AFTER TREATMENT FOR PROSTATE CANCER" @default.
• W2095388504 cites W1883868988 @default.
• W2095388504 cites W1970400785 @default.
• W2095388504 cites W1979819510 @default.
• W2095388504 cites W1982757300 @default.
• W2095388504 cites W1985040614 @default.
• W2095388504 cites W1992119768 @default.
• W2095388504 cites W1993657718 @default.
• W2095388504 cites W1994482727 @default.
• W2095388504 cites W1994948084 @default.
• W2095388504 cites W1995780409 @default.
• W2095388504 cites W1996422254 @default.
• W2095388504 cites W2006081762 @default.
• W2095388504 cites W2018445655 @default.
• W2095388504 cites W2022266950 @default.
• W2095388504 cites W2026566205 @default.
• W2095388504 cites W2027690452 @default.
• W2095388504 cites W2028242654 @default.
• W2095388504 cites W2028585120 @default.
• W2095388504 cites W2030553943 @default.
• W2095388504 cites W2034472089 @default.
• W2095388504 cites W2050137994 @default.
• W2095388504 cites W2055357148 @default.
• W2095388504 cites W2058671060 @default.
• W2095388504 cites W2062531523 @default.
• W2095388504 cites W2066899660 @default.
• W2095388504 cites W2071879495 @default.
• W2095388504 cites W2076071526 @default.
• W2095388504 cites W2078246231 @default.
• W2095388504 cites W2084591997 @default.
• W2095388504 cites W2092720094 @default.
• W2095388504 cites W2096409687 @default.
• W2095388504 cites W2103003357 @default.
• W2095388504 cites W2108776877 @default.
• W2095388504 cites W2134741012 @default.
• W2095388504 cites W2140680429 @default.
• W2095388504 cites W2144704795 @default.
• W2095388504 cites W2153685427 @default.
• W2095388504 cites W2161749968 @default.
• W2095388504 cites W2167968708 @default.
• W2095388504 cites W2337912524 @default.
• W2095388504 cites W30668925 @default.
• W2095388504 cites W4239319701 @default.
• W2095388504 cites W4245681340 @default.
• W2095388504 cites W4249663626 @default.
• W2095388504 cites W4293168096 @default.
• W2095388504 cites W4320801101 @default.
• W2095388504 cites W4377834532 @default.
• W2095388504 doi "https://doi.org/10.1097/01.ju.0000157323.55611.23" @default.
• W2095388504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15821460" @default.
• W2095388504 hasPublicationYear "2005" @default.
• W2095388504 type Work @default.
• W2095388504 sameAs 2095388504 @default.
• W2095388504 citedByCount "47" @default.
• W2095388504 countsByYear W20953885042012 @default.
• W2095388504 countsByYear W20953885042013 @default.
• W2095388504 countsByYear W20953885042014 @default.
• W2095388504 countsByYear W20953885042015 @default.
• W2095388504 countsByYear W20953885042016 @default.
• W2095388504 countsByYear W20953885042017 @default.
• W2095388504 countsByYear W20953885042018 @default.
• W2095388504 countsByYear W20953885042019 @default.
• W2095388504 countsByYear W20953885042021 @default.
• W2095388504 countsByYear W20953885042023 @default.
• W2095388504 crossrefType "journal-article" @default.
• W2095388504 hasAuthorship W2095388504A5006151030 @default.
• W2095388504 hasAuthorship W2095388504A5016407136 @default.
• W2095388504 hasAuthorship W2095388504A5021503571 @default.
• W2095388504 hasAuthorship W2095388504A5034586842 @default.
• W2095388504 hasAuthorship W2095388504A5049646055 @default.
• W2095388504 hasAuthorship W2095388504A5059255743 @default.
• W2095388504 hasConcept C121608353 @default.
• W2095388504 hasConcept C126322002 @default.
• W2095388504 hasConcept C143998085 @default.
• W2095388504 hasConcept C177713679 @default.
• W2095388504 hasConcept C2776235491 @default.
• W2095388504 hasConcept C2780192828 @default.
• W2095388504 hasConcept C2781406297 @default.
• W2095388504 hasConcept C509974204 @default.
• W2095388504 hasConcept C71924100 @default.
• W2095388504 hasConceptScore W2095388504C121608353 @default.
• W2095388504 hasConceptScore W2095388504C126322002 @default.
• W2095388504 hasConceptScore W2095388504C143998085 @default.
• W2095388504 hasConceptScore W2095388504C177713679 @default.
• W2095388504 hasConceptScore W2095388504C2776235491 @default.
• W2095388504 hasConceptScore W2095388504C2780192828 @default.
• W2095388504 hasConceptScore W2095388504C2781406297 @default.
• W2095388504 hasConceptScore W2095388504C509974204 @default.

• next